Angiostatic collagen modulators
US5021404A · kind A · utility
59Cited by
1References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 20, 1988 |
| Grant date | Jun 4, 1991 |
| Priority date | — |
| Expiry date | Apr 20, 2008 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Angiostatic compounds are potentiated by collagen matrix metabolism modulators including: PA1 a) proline analogs which inhibit proline hydroxylation when substituted for proline in collagen; PA1 b) inhibitors of proline hydroxylase; PA1 c) inhibitors of collagen cross-linking; and PA1 d) all trans-retinoic acid. In methods and therapeutic compositions for inhibiting angiogenesis in a mammal, the collagen matrix modulator is administered with an angiostatic steroid or with heparin (including angiostatic heparin fragments of six or more sugar units, and synthetic fragments).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.